Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study

Alison M. Mondul, Corinne E. Joshu, John R. Barber, Anna E. Prizment, Nrupen A. Bhavsar, Elizabeth Selvin, Aaron R. Folsom, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

Lipid-lowering medications, particularly statins, may protect against aggressive prostate cancer. Fatal prostate cancer, the most clinically relevant outcome, remains understudied for this association. We prospectively studied lipid-lowering medication use and both incident and fatal prostate cancer in black and white men in the Atherosclerosis Risk in Communities (ARIC) study. A total of 6,518 men without cancer at visit 2 (1990-1992), the start of the statin era, were followed for prostate cancer incidence and death through 2012. Medication use was collected during study visits and telephone calls at up to nine time points during followup. Cox regression was used to estimate HR and 95% confidence intervals (CI) of total (white N ¼ 541, black N ¼ 259) and fatal (white N ¼ 56, black N ¼ 34) prostate cancer overall and by race. Lipid-lowering medication use was modeled as time-dependent current use or duration (never, <10, and 10 years). By visit 4 (1996-1998), 21% of white and 11% of black men had used a lipid-lowering medication, mostly statins. There was a suggestion that current users were less likely to die from prostate cancer than nonusers (HR ¼ 0.67, 95% CI ¼ 0.42-1.07) after multivariable adjustment. We observed no statistically significant differences between black and white men. Current use was not associated with incident prostate cancer, although long-term use was statistically significantly inversely associated with incidence (HR ¼ 0.68; 95% CI ¼ 0.50-0.92). Long-term lipid-lowering medication use was associated with lower risk of prostate cancer. Current use was possibly associated with fatal prostate cancer. Cancer Prev Res; 11(12); 779-88. 2018 AACR.

Original languageEnglish (US)
Pages (from-to)779-788
Number of pages10
JournalCancer Prevention Research
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Prostatic Neoplasms
Atherosclerosis
Lipids
Pharmaceutical Preparations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Confidence Intervals
hydroquinone
Incidence
Telephone
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study. / Mondul, Alison M.; Joshu, Corinne E.; Barber, John R.; Prizment, Anna E.; Bhavsar, Nrupen A.; Selvin, Elizabeth; Folsom, Aaron R.; Platz, Elizabeth A.

In: Cancer Prevention Research, Vol. 11, No. 12, 01.12.2018, p. 779-788.

Research output: Contribution to journalArticle

Mondul, Alison M. ; Joshu, Corinne E. ; Barber, John R. ; Prizment, Anna E. ; Bhavsar, Nrupen A. ; Selvin, Elizabeth ; Folsom, Aaron R. ; Platz, Elizabeth A. / Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study. In: Cancer Prevention Research. 2018 ; Vol. 11, No. 12. pp. 779-788.
@article{703ee1ea5e67404e9926285deaf7ee93,
title = "Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study",
abstract = "Lipid-lowering medications, particularly statins, may protect against aggressive prostate cancer. Fatal prostate cancer, the most clinically relevant outcome, remains understudied for this association. We prospectively studied lipid-lowering medication use and both incident and fatal prostate cancer in black and white men in the Atherosclerosis Risk in Communities (ARIC) study. A total of 6,518 men without cancer at visit 2 (1990-1992), the start of the statin era, were followed for prostate cancer incidence and death through 2012. Medication use was collected during study visits and telephone calls at up to nine time points during followup. Cox regression was used to estimate HR and 95{\%} confidence intervals (CI) of total (white N ¼ 541, black N ¼ 259) and fatal (white N ¼ 56, black N ¼ 34) prostate cancer overall and by race. Lipid-lowering medication use was modeled as time-dependent current use or duration (never, <10, and 10 years). By visit 4 (1996-1998), 21{\%} of white and 11{\%} of black men had used a lipid-lowering medication, mostly statins. There was a suggestion that current users were less likely to die from prostate cancer than nonusers (HR ¼ 0.67, 95{\%} CI ¼ 0.42-1.07) after multivariable adjustment. We observed no statistically significant differences between black and white men. Current use was not associated with incident prostate cancer, although long-term use was statistically significantly inversely associated with incidence (HR ¼ 0.68; 95{\%} CI ¼ 0.50-0.92). Long-term lipid-lowering medication use was associated with lower risk of prostate cancer. Current use was possibly associated with fatal prostate cancer. Cancer Prev Res; 11(12); 779-88. 2018 AACR.",
author = "Mondul, {Alison M.} and Joshu, {Corinne E.} and Barber, {John R.} and Prizment, {Anna E.} and Bhavsar, {Nrupen A.} and Elizabeth Selvin and Folsom, {Aaron R.} and Platz, {Elizabeth A}",
year = "2018",
month = "12",
day = "1",
doi = "10.1158/1940-6207.CAPR-17-0396",
language = "English (US)",
volume = "11",
pages = "779--788",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study

AU - Mondul, Alison M.

AU - Joshu, Corinne E.

AU - Barber, John R.

AU - Prizment, Anna E.

AU - Bhavsar, Nrupen A.

AU - Selvin, Elizabeth

AU - Folsom, Aaron R.

AU - Platz, Elizabeth A

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Lipid-lowering medications, particularly statins, may protect against aggressive prostate cancer. Fatal prostate cancer, the most clinically relevant outcome, remains understudied for this association. We prospectively studied lipid-lowering medication use and both incident and fatal prostate cancer in black and white men in the Atherosclerosis Risk in Communities (ARIC) study. A total of 6,518 men without cancer at visit 2 (1990-1992), the start of the statin era, were followed for prostate cancer incidence and death through 2012. Medication use was collected during study visits and telephone calls at up to nine time points during followup. Cox regression was used to estimate HR and 95% confidence intervals (CI) of total (white N ¼ 541, black N ¼ 259) and fatal (white N ¼ 56, black N ¼ 34) prostate cancer overall and by race. Lipid-lowering medication use was modeled as time-dependent current use or duration (never, <10, and 10 years). By visit 4 (1996-1998), 21% of white and 11% of black men had used a lipid-lowering medication, mostly statins. There was a suggestion that current users were less likely to die from prostate cancer than nonusers (HR ¼ 0.67, 95% CI ¼ 0.42-1.07) after multivariable adjustment. We observed no statistically significant differences between black and white men. Current use was not associated with incident prostate cancer, although long-term use was statistically significantly inversely associated with incidence (HR ¼ 0.68; 95% CI ¼ 0.50-0.92). Long-term lipid-lowering medication use was associated with lower risk of prostate cancer. Current use was possibly associated with fatal prostate cancer. Cancer Prev Res; 11(12); 779-88. 2018 AACR.

AB - Lipid-lowering medications, particularly statins, may protect against aggressive prostate cancer. Fatal prostate cancer, the most clinically relevant outcome, remains understudied for this association. We prospectively studied lipid-lowering medication use and both incident and fatal prostate cancer in black and white men in the Atherosclerosis Risk in Communities (ARIC) study. A total of 6,518 men without cancer at visit 2 (1990-1992), the start of the statin era, were followed for prostate cancer incidence and death through 2012. Medication use was collected during study visits and telephone calls at up to nine time points during followup. Cox regression was used to estimate HR and 95% confidence intervals (CI) of total (white N ¼ 541, black N ¼ 259) and fatal (white N ¼ 56, black N ¼ 34) prostate cancer overall and by race. Lipid-lowering medication use was modeled as time-dependent current use or duration (never, <10, and 10 years). By visit 4 (1996-1998), 21% of white and 11% of black men had used a lipid-lowering medication, mostly statins. There was a suggestion that current users were less likely to die from prostate cancer than nonusers (HR ¼ 0.67, 95% CI ¼ 0.42-1.07) after multivariable adjustment. We observed no statistically significant differences between black and white men. Current use was not associated with incident prostate cancer, although long-term use was statistically significantly inversely associated with incidence (HR ¼ 0.68; 95% CI ¼ 0.50-0.92). Long-term lipid-lowering medication use was associated with lower risk of prostate cancer. Current use was possibly associated with fatal prostate cancer. Cancer Prev Res; 11(12); 779-88. 2018 AACR.

UR - http://www.scopus.com/inward/record.url?scp=85058326152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058326152&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-17-0396

DO - 10.1158/1940-6207.CAPR-17-0396

M3 - Article

C2 - 30327368

AN - SCOPUS:85058326152

VL - 11

SP - 779

EP - 788

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 12

ER -